|
DR. Dahl is an accomplished biotech/pharma executive with expertise in early stage ventures, including technical analysis of products and technologies, business strategy and clinical trial strategies and design. Dr. Dahl has served in senior management positions including President/CEO and Vice President roles in successful startups including Synta Pharmaceuticals, Single Pixel Biomedical (acquired by Synta), and Lexigen Pharmaceuticals (acquired by Merck KGaA), helping to operationalize founding product ideas, obtain funding, and create development capabilities through clinical proof of concept in preparation for acquisition or further funding for continued development. Dr. Dahl obtained his PhD from the Johns Hopkins University, and has held academic positions at Tufts University Medical, Dental and Veterinary Schools and Tufts-New England Medical Center. | 